ASCO Conference Coverage
Filter News By:
Featured News
View all
More News
(ESMO) June 25, 2019 - Results of the NEOSTAR and LCMC3 studies that tested neoadjuvant immune checkpoint blockade in resectable non-small cell lung cancer (NSCLC) were presented at 2019 ASCO Annual Meeting.
(Medscape Medical News) June 13, 2019 - The federal government's Oncology Care Model (OCM) is based on the idea that you can motivate clinicians with cash rewards to improve care and reduce costs.
(Xconomy San Diego) June 12, 2019 - Oncternal Therapeutics has joined the growing ranks of San Diego biotechs to go public, but it didn’t go through an IPO to get there.
(Medscape Medical News) June 10, 2019 - Ashley Glode, PharmD, a pharmacist in the gastrointestinal clinic at the University of Colorado Cancer Center, Anshutz, says marijuana is not a taboo topic in her state, where medical use was...
(Medscape Medical News) June 7, 2019 - Since the inception of the Open Payments program, fewer American medical oncologists appear to be engaging with industry, new findings show.
(Physician’s Weekly) June 5, 2019 - One of the repeated themes of the American Society of Clinical Oncology meeting here was the need for baseline testing of any target that can inform truly precision use of targeted therapies.
(Washington Post/Bloomberg) June 5, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO), which wrapped up Tuesday, is one of the drug industry’s most prominent platforms for showcasing promising cancer research...
(UNC LCCC) June 2, 2019 - Preliminary results from a University of North Carolina Lineberger Comprehensive Cancer Center study found that just 15 percent of a group of men in North Carolina with early-stage prostate cancer who choose...
(The Center For Biosimilars) June 6, 2019 - During this week’s 2019 American Society of Clinical Oncology Annual Meeting, researchers reported on the cardiac safety of Amgen’s biosimilar trastuzumab, ABP 980 (approved in the European...
[ICR [UK]) June 5, 2019 - A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Some 80 per cent of men with prostate cancer whose...
Expert Videos

OBR Tweets

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj

Sep 24
Maha Hussain, MD, of @LurieCancer provides perspective on the Phase III PROfound study presented at #ESMO20 https://t.co/NerWJUf67S

Aug 25
At the ASCO20 Virtual Education Program, Nilanjan Ghosh, MD, PhD, a hematologist-oncologist at the @LevineCancer, p… https://t.co/o2s69MGfrW

Aug 25
At the #ASCO20 Virtual Education Program, Jaleh Fallah @Jaleh_Fallah, MD, a Hematology/Oncology Fellow at the Cleve… https://t.co/QDkyebDuvp

Aug 25
The financial toxicity that patients and oncology practices are potentially exposed to due to the high costs associ… https://t.co/QA8A13PAGT

Aug 25
At separate #AACR and #COA virtual meetings held in July, participants discussed the challenges of providing cancer… https://t.co/8fs8SKl65a